Hepatocellular carcinoma(HCC)was the sixth most common cancer and the third cause of cancer-related deaths worldwide in 2020.Liver resection and transplantation remain the cornerstone for patients with early-stage dis...Hepatocellular carcinoma(HCC)was the sixth most common cancer and the third cause of cancer-related deaths worldwide in 2020.Liver resection and transplantation remain the cornerstone for patients with early-stage disease and represent the only option for potential cure in HCC.However,fewer than 10%of patients are considered suitable for surgery at the time of diagnosis.Locoregional therapies,defined as minimally invasive image-guided liver tumour-directed procedures,are integral to in the management of HCC.This review discusses the role of locoregional therapies in HCC management in the emergence of immune and systemic treatments.展开更多
文摘Hepatocellular carcinoma(HCC)was the sixth most common cancer and the third cause of cancer-related deaths worldwide in 2020.Liver resection and transplantation remain the cornerstone for patients with early-stage disease and represent the only option for potential cure in HCC.However,fewer than 10%of patients are considered suitable for surgery at the time of diagnosis.Locoregional therapies,defined as minimally invasive image-guided liver tumour-directed procedures,are integral to in the management of HCC.This review discusses the role of locoregional therapies in HCC management in the emergence of immune and systemic treatments.
